---
title: "Biotech Stock Blasting Off After Late-Stage Trial Results"
description: "Biotech stock Celcuity Inc (NASDAQ:CELC) surged 221% to $43.76 following positive phase 3 trial results for its breast cancer therapy, gedatolisib, which may receive FDA approval soon. The treatment s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250444104.md"
published_at: "2025-07-28T14:37:32.000Z"
---

# Biotech Stock Blasting Off After Late-Stage Trial Results

> Biotech stock Celcuity Inc (NASDAQ:CELC) surged 221% to $43.76 following positive phase 3 trial results for its breast cancer therapy, gedatolisib, which may receive FDA approval soon. The treatment showed a 76% reduction in disease progression risk. CELC is trading at record highs, surpassing its previous peak of $33.01. Despite increased options activity, puts are outpacing calls nine to one, indicating potential correction bets. Analysts maintain a "buy" or "strong buy" rating, but the 12-month price target of $32 is now below current levels.

Biotech stock **Celcuity Inc (NASDAQ:CELC)** is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes will have Food & Drug Administration (FDA) approval by the end of the year.

The treatment demonstrated a favorable safety profile in comparison to similar drugs, and the triple combo of gedatolisib, Pfizer's (PFE) Ibrance, and AstraZeneca's (AZN) endocrine therapy Faslode reduced the risk of disease progression or death by 76%.

Headed for its best day ever, CELC is trading at record highs after blowing past its previous June 25, 2021 all-time peak of $33.01. The equity is also breaking into positive territory year-over-year.

Celcuity is seeing much more **options activity** than usual, though puts are outweighing calls nine to one as traders appear to bet on a correction. The most popular contract today is the August 25 put, with new positions being bought to open there.

Analysts have yet to chime in, though all eight in coverage already carry a "buy" or "strong buy" rating. The 12-month consensus price target of $32 is now a discount to current levels, however, so bull notes could keep the wind at the equity's back.

### Related Stocks

- [CELC.US - Celcuity](https://longbridge.com/en/quote/CELC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Dir Buller Sells 3,000 ($317.1K) Of Celcuity Inc [CELC] | Buller Richard E Director of Celcuity Inc [CELC] filed a Form 4 on December 9, 2025 with the Securities and Exchange Com | [Link](https://longbridge.com/en/news/269137964.md) |
| Celcuity Inc. Director Richard E. Buller Reports Sale of Common Shares | Richard E. Buller, Director of Celcuity Inc., has reported the sale of common shares of the company. The details of the  | [Link](https://longbridge.com/en/news/269137759.md) |
| Celcuity Inc. Director David Dalvey Reports Sale of Common Shares | David Dalvey, a Director at Celcuity Inc., reported the sale of common shares of the company. This information was publi | [Link](https://longbridge.com/en/news/267235804.md) |
| Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock | Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares for $2,400,600 on January 27, reducing his ownersh | [Link](https://longbridge.com/en/news/274217612.md) |
| Celcuity Announces Updated Phase 3 VIKTORIA-1 Trial Results for Gedatolisib in HR+/HER2- Advanced Breast Cancer | Celcuity Inc. announced updated Phase 3 VIKTORIA-1 trial results for gedatolisib in HR+/HER2- advanced breast cancer. Th | [Link](https://longbridge.com/en/news/267582985.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.